Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematological Malignancy & Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IRF4/MUM1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IRF4 Recombinant Protein (DBD/IAD domains) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for DNA-binding and protein interaction assays. |
View IRF4 Products |
| Gene Delivery | IRF4 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation in myeloma models. |
View IRF4 Products |
| Benchmark Ab | Anti-IRF4 (Sequence of Clinical Benchmarks) Recombinant positive control antibody for flow cytometry, IHC, and Western Blotting. |
View IRF4 Products |
| Validator | IRF4 siRNA Set For target knockdown verification and specificity profiling in cell-based assays. |
View IRF4 Products |
| Related Target A | CRBN (Cereblon) Primary E3 ligase substrate receptor; critical for IMiD-mediated or PROTAC-mediated IRF4 downregulation. |
View CRBN Products |
| Related Target B | IKZF1 (Ikaros) Upstream transcription factor regulating IRF4 expression; essential for resistance bypass screening. |
View IKZF1 Products |
| Related Target C | IKZF3 (Aiolos) Co-regulator of IRF4 in lymphoid lineages; key node in multiple myeloma therapeutic pathways. |
View IKZF3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Target Access & Delivery | Lentiviral vectors optimized for high-efficiency transduction in suspension myeloma cell lines (e.g., MM.1S, RPMI-8226). |
| Protein-DNA Interaction Verification | DNA-Binding Domain (DBD) recombinant proteins strictly verified by mass spectrometry and sequence analysis for binding site fidelity. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and validated siRNA controls included in the screening workflow. |
| Off-Target Cross-Screening | Homologous IRF family proteins (IRF1, IRF2, IRF8) panel available to ensure screening selectivity. |
Live IRF4/MUM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IRF4/MUM1 therapeutics is intensifying, with major players shifting focus from traditional immunomodulatory drugs (IMiDs) to direct molecular glues, PROTACs, and antisense oligonucleotides (ASOs). As first-generation indirect therapies reach clinical maturity, the next wave of R&D is targeting direct degradation of the IRF4 transcription factor to overcome acquired resistance in multiple myeloma and diffuse large B-cell lymphoma (DLBCL).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glues / PROTACs | Bristol Myers Squibb, Monte Rosa Therapeutics | Multiple Myeloma, DLBCL | Ternary complex validation (Requires high-purity CRBN and IRF4 proteins) |
| Antisense Oligonucleotides (ASO) | Ionis Pharmaceuticals | Hematological Malignancies | Target knockdown confirmation (Requires validated IRF4 siRNA and Lentivirus) |
| TCR-T / Immunotherapy | Academic Institutions, Biotech Startups | MUM1-positive Lymphomas | Epitope presentation validation (Requires sequence-verified MUM1/IRF4 peptides/proteins) |